Evidence map›Paper›PMID 33592678›Full record

ArticlePacing and clinical electrophysiology : PACE2021

Outcomes of cardiac resynchronization therapy in patients with chemotherapy-induced cardiomyopathy.

Fatima M Ezzeddine, Antoine N Saliba, Vaibhav Jain, Hector R Villarraga, Joerg Herrmann, Samuel J Asirvatham, Yong-Mei Cha

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pacing and clinical electrophysiology : PACE, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Effectiveness of cardiac resynchronization therapy in cancer therapy-related cardiac dysfunction: a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Pooled it
  2. Efficacy and safety of cardiac resynchronization therapy in chemotherapy-induced cardiomyopathy: A systematic review.Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc · 2023
    Pooled it
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fatima M EzzeddineDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0002-6204-4557
Antoine N SalibaDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Vaibhav JainDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Hector R VillarragaDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Joerg HerrmannDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Samuel J AsirvathamDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0001-9835-5536
Yong-Mei ChaDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0002-5897-9464

Funding

TrAstuzumab Cardiomyopathy Therapeutic Intervention with Carvedilol (TACTIC) TrialR01CA233610 · NCI · MAYO CLINIC ROCHESTER · PI HERRMANN, JOERG, RUDDY, KATHRYN JEAN · 2019 to 2024
$4.3M
NCI NIH HHS R01 CA233610
6 · The paper itself

Abstract

backgroundSeveral chemotherapy agents are associated with the development of non-ischemic cardiomyopathy (NIC). When chemotherapy-induced cardiomyopathy (CHIC) is associated with left bundle branch block (LBBB) and a left ventricular ejection fraction (LVEF) 35% or lower, cardiac resynchronization therapy (CRT) is often utilized to improve cardiac function and relieve symptoms.

objectiveTo determine the echocardiographic and clinical outcomes of CRT in patients with CHIC.

methodsThe study included 29 patients with CHIC (CHIC group) and 58 patients with other types of NIC (control group) who underwent CRT implantation between 2004 and 2017. The primary endpoints were changes in LVEF, left ventricular end-systolic diameter (LVESD), and left ventricular end-diastolic diameter (LVEDD) at 6-18 months after CRT. The secondary outcomes included changes in left ventricular global longitudinal strain (GLS), systolic strain rate (SRS), early diastolic strain rate (SRE), and overall survival.

resultsOut of 29 patients with CHIC, 62.1% received chemotherapy for lymphoma, 13.7% for breast cancer, and 24.1% for sarcoma. The agent implicated in 93.1% of the patients was an anthracycline. Half of the patients had LBBB. The mean baseline LVEF was 28% ± 8%. The mean baseline QRS duration was 146 ± 26 ms. Twenty-eight patients had post-CRT follow-up data. CRT was associated with improvement in echocardiographic outcomes in the CHIC group and the control group. There was no difference in overall survival between the two groups (log-rank p = .148).

conclusionCRT improves left ventricular function and reverses remodeling in patients with CHIC.

Indexed as

AgedAntineoplastic AgentsBreast NeoplasmsCardiac Resynchronization TherapyCardiomyopathiesEchocardiographyElectrocardiographyFemaleHumansLymphomaMaleRetrospective StudiesSarcomaAntineoplastic Agentscardiac remodelingcardiac resynchronization therapycardiomyopathychemotherapyejection fractionstrain

Identifiers

PMID33592678
PMCPMC8772340

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.